Samsung Biologics acquires drug product manufacturing approval from U.S. FDA
Samsung Biologics(CEO Tae-Han Kim) announced on the 25th that they acquired manufacturing approval of its first finished drug product from the Food and Drug Administration, a federal agency of the United States Department of Health and Human Services.
Previously, the company acquired product app...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.